Press Releases August 4, 2026 06:00 AM

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

Biodesix to present at Canaccord Genuity’s 46th Annual Growth Conference

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BDSX

Biodesix, Inc., a diagnostics solutions company, announced its leadership team will participate in a fireside chat and investor meetings at Canaccord Genuity’s 46th Annual Growth Conference on August 11-12, 2026. The presentation will be webcast live and focus on the company’s diagnostic solutions, including lung disease tests and development services supporting biopharmaceutical and life sciences sectors.

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
BDSX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Biodesix leadership to present and engage with investors at Canaccord Genuity’s Growth Conference.
  • Company focuses on diagnostic tests for lung diseases, including Nodify Lung® and IQLung®.
  • Development services support biopharmaceutical, life sciences, and research institutions in developing diagnostics and therapeutics.

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity’s 46th Annual Growth Conference, which will be held from August 11-12, 2026.

Canaccord Genuity’s 46th Annual Growth Conference
Fireside Chat Date: Wednesday, August 12, 2026
Fireside Chat Time: 3:30 PM ET
Location: InterContinental Boston, Boston, MA

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of Biodesix website at Biodesix.com.

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
[email protected]
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
[email protected]
(339) 970-2843


Risks

  • Investor reception and engagement at the conference could impact future investment and stock performance.
  • Dependence on adoption and commercial success of lung disease diagnostic tests.
  • Potential competitive pressures from other diagnostic and biotech firms in the healthcare sector.

More from Press Releases

UniFirst Declares Increased Cash Dividends Oct 30, 2026 Orange County Bancorp, Inc. Announces Record Third Quarter Earnings Oct 28, 2026 ARMOUR Residential REIT, Inc. Announces Q3 Results And September 30, 2026 Financial Position Oct 21, 2026 Eagle Bancorp, Inc. Announces Third Quarter 2026 Results Oct 21, 2026 iPower Opens New AI Era with Five-Year Services LOI Targeting $21.90 Million in Potential Annualized Services Oct 15, 2026